2019
DOI: 10.7759/cureus.4999
|View full text |Cite
|
Sign up to set email alerts
|

Hydrochlorothiazide vs Venlafaxine: Drug-induced Bullous Pemphigoid

Abstract: Pemphigoid group of dermatologic conditions is a group of autoimmune skin disorders resulting in blistering skin conditions. The two diseases that fall under this category are bullous pemphigoid and pemphigus vulgaris. While there are many similarities in these two disorders, there are numerous pathologic and biochemical differences which help us differentiate between these disorders. In this case report, we report a usual manifestation of bullous pemphigoid in a 72-year-old female secondary to use of a well-k… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 5 publications
1
0
0
Order By: Relevance
“…4,5 Although around 50 medications have been implicated in drug-induced BP, 14 less is known about the delay of symptom onset from initiation of the culprit medication; reports have ranged from 6 weeks to several years. 15 Similar to other cases of BP secondary to pembrolizumab, our patient was successfully treated with systemic steroids. Because of the unpredictable timeline of the development of BP secondary to pembrolizumab, it is important to monitor for cutaneous symptoms while a patient is receiving the drug.…”
Section: Discussionsupporting
confidence: 78%
“…4,5 Although around 50 medications have been implicated in drug-induced BP, 14 less is known about the delay of symptom onset from initiation of the culprit medication; reports have ranged from 6 weeks to several years. 15 Similar to other cases of BP secondary to pembrolizumab, our patient was successfully treated with systemic steroids. Because of the unpredictable timeline of the development of BP secondary to pembrolizumab, it is important to monitor for cutaneous symptoms while a patient is receiving the drug.…”
Section: Discussionsupporting
confidence: 78%